What's next for TAVR? What trends should clinicians be focused on as time goes on? Kapadia shared his perspective in a new interview. 

The device, which gained CE mark approval in Europe in May 2021, features a new-look fabric cuff designed to keep the risk of paravalvular leak (PVL) at a minimum.

Brian Lindman, MD, discusses the tracking of TAVR devices for signs of deterioration and how to assess long-term durability.

The study, published in JACC: Cardiovascular Interventions, focused on data from more than 3,500 TAVR patients. 

A new analysis in Circulation: Cardiovascular Interventions examined rehospitalization rates after AVR, noting that they are consistently associated with worse outcomes and a higher risk of patient mortality.

Gabler, a Texas native, has two decades of experience in the cardiology space, spending the last 11 years with Edwards Lifesciences. He has also previously worked for both Medtronic and Boston Scientific.